FDA's draft guidance on laboratory‐developed tests increases clinical and economic risk to adoption of pharmacogenetic testing

Publisher： John Wiley & Sons Inc

E-ISSN： 1552-4604|55|7|725-727

ISSN： 0091-2700

Source： JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol.55, Iss.7, 2015-07, pp. : 725-727

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

FDA oversight of laboratory‐developed tests will facilitate adoption of pharmacogenetic testing into routine clinical care

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 7, 2015-07 ,pp. : 728-730

John Wiley & Sons Inc

Access to resources Recommend Favorite

US Food and Drug Administration regulatory oversight of laboratory‐developed tests: Commentary on the draft guidance

By  

CANCER CYTOPATHOLOGY, Vol. 123, Iss. 10, 2015-10 ,pp. : 573-575

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical pharmacy consultation for pharmacogenetic testing

By Shin Jaekyu   Kayser Steven R  

Personalized Medicine, Vol. 6, Iss. 2, 2009-03 ,pp. : 183-192

Future Medicine

Access to resources Recommend Favorite

Facilitators and Barriers to the Adoption of Pharmacogenetic Testing in an Inner‐City Population

By  

PHARMACOTHERAPY: THE JOURNAL OF HUMAN PHARMACOLOGY AND DRUG THERAPY, Vol. 38, Iss. 2, 2018-02 ,pp. : 205-216

John Wiley & Sons Inc

Access to resources Recommend Favorite

Community pharmacists‘ attitudes towards clinical utility and ethical implications of pharmacogenetic testing

By Tuteja Sony   Haynes Kevin   Zayac Cara   Sprague Jon E   Bernhardt Barbara   Pyeritz Reed  

Personalized Medicine, Vol. 10, Iss. 8, 2013-11 ,pp. : 793-800

Future Medicine

Access to resources Recommend Favorite